Growing Number of Americans Are Trying Weight-Loss Drugs

  • 16 days ago
Growing , Number of Americans Are Trying , Weight-Loss Drugs.
According to a recent poll, six percent of adults
in the United States have already tried Ozempic
or other brand name weight loss medications.
According to a recent poll, six percent of adults
in the United States have already tried Ozempic
or other brand name weight loss medications.
'Newsweek' reports that the Gallup poll numbers
suggest that approximately 15.5 million Americans have
used or are using an injectable diabetes medication. .
'Newsweek' reports that the Gallup poll numbers
suggest that approximately 15.5 million Americans have
used or are using an injectable diabetes medication. .
According to the poll, three percent
of those users are specifically
using the drug for weight loss.
The poll found that people between the ages
of 40 and 64 are the most likely to try Ozempic
or competitors, like Wegovy or Saxenda. .
In 2017, the U.S. Food and Drug
Administration (FDA) approved Ozempic
to treat cardiovascular disease and diabetes. .
'Newsweek' reports that while Ozempic has
not been approved for weight-loss purposes,
its competitor Wegovy was approved in 2021. .
'Newsweek' reports that while Ozempic has
not been approved for weight-loss purposes,
its competitor Wegovy was approved in 2021. .
Both drugs rely upon the active ingredient
semaglutide, however, Wegovy contains
a higher amount than Ozempic.
Both drugs rely upon the active ingredient
semaglutide, however, Wegovy contains
a higher amount than Ozempic.
The popularity of the drug has resulted
in various makers reporting shortages. .
The drug companies didn't
anticipate how popular
these drugs would become, Sue Decotiis, Triple-board-certified medical
weight-loss doctor in New York City, via 'Newsweek'.
Since they are being used
for many issues, like diabetes,
heart failure, obesity,
this exacerbates the
shortages significantly, Sue Decotiis, Triple-board-certified medical
weight-loss doctor in New York City, via 'Newsweek'

Recommended